SCHEMBL5034834

SCHEMBL5034834

CCOC(=O)c1cnc(Nc2ccc(OC)c(OC)c2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
KDM4E B2RXH2 3/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
GAA P10253 1/20 0.53
AURKA O14965 1/20 0.49
AURKB Q96GD4 1/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.48
SHMT2 P34897 1/20 0.47
DHODH Q02127 5/20 0.47
ALDH1A1 P00352 2/20 0.47
CDC7 O00311 1/20 0.47
DBF4 Q9UBU7 1/20 0.47
HSD17B10 Q99714 2/20 0.46
HPGD P15428 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5038697 0.83 MAPK13 (0.52) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL5035841 0.82 MAPK13 (0.56) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL5041113 0.81 MAPT (0.57) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL10235581 0.80 DHODH (0.58) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL23334316 0.78 DHODH (0.56) MAPTSMN1; SMN2KDM4EKMT2AAURKA
SCHEMBL5035870 0.77 LMNA (0.71) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL29977658 0.77 AURKA (0.45) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL12291072 0.76 CDC7 (0.55) MAPTSMN1; SMN2AURKAAURKBRAB9A
SCHEMBL15541887 0.75 ALDH1A1 (0.47) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL22510110 0.75 HPGD (0.63) MAPTSMN1; SMN2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 MAPT 3183/4885SMN1; SMN2 3460/4885KDM4E 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.